Stiripentol

  • TRADE NAME: Diacomit (Biocodex SA)
  • INDICATIONS: treatment of seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam.
  • HALF-LIFE: 4.5–13 hours

FDA APPROVAL DATE: 08/20/2018

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Clobazam

PREGNANCY CATEGORY: N/A
Based on animal data, may cause fetal harm

Our database has 33 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

MUCOSAL
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
HEMATOLOGIC
OTHER


Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric